Raydiant Oximetry is a technology company.
Raydiant Oximetry has raised $13.0M across 2 funding rounds.
Raydiant Oximetry has raised $13.0M in total across 2 funding rounds.
Raydiant Oximetry has raised $13.0M in total across 2 funding rounds.
Raydiant Oximetry's investors include Avestria Ventures, Global Health Impact Fund.
Raydiant Oximetry is a clinical-stage medical device company based in San Ramon, California, developing Lumerah™, a low-cost, non-invasive sensor that directly measures fetal oxygen saturation levels from the mother's abdomen during childbirth.[1][2][4] It targets obstetric providers to address limitations in current fetal heart rate monitoring, which has an 89% false positive rate for detecting distress, leading to unnecessary cesareans and rising maternal/infant mortality without reducing neurologic injuries.[2][4] The company serves hospitals and clinicians, solving the lack of direct fetal oxygenation data—a vital sign missing from 50-year-old electronic fetal monitoring tech—potentially becoming the standard of care.[1][2][4] Growth includes a $5.6M Series A led by VCapital, grants from the Bill & Melinda Gates Foundation ($1M), Ireland government (~$3M), NIH SBIR funding, and partnerships like GE HealthCare for joint development; leadership transitioned with Michael Nagel as CEO in September 2025.[2][3]
Founded by Neil P. Ray, MD, an anesthesiologist practicing since 2005, Raydiant Oximetry emerged from his clinical observations of unmet needs in labor and delivery monitoring.[1] Lacking engineering or business expertise, Ray pitched his idea to the Fogarty Institute for Innovation, a Bay Area non-profit accelerator, which provided crucial early support as a Fogarty graduate.[1][2] The concept builds on mature pulse oximetry tech—highlighted during COVID-19 for skin tone biases—adapted noninvasively for fetal use via patented optical sensing and biophotonics/machine learning.[1][2][5] Pivotal early traction came from SBIR grants, enabling prototype development to predict maternal/fetal distress more reliably than heart rate patterns alone.[1][5]
Raydiant rides the wave of precision maternal-fetal medicine, countering U.S. trends of rising C-section rates (6-fold increase over 50 years from flawed monitoring) and maternal/infant mortality, amid demands for equitable, data-driven obstetrics post-COVID oximetry scrutiny.[1][2] Timing aligns with global health innovation pushes—e.g., Gates Foundation focus on childbirth safety in low-resource settings—and U.S. policy support via SBIR for critical needs.[1][2] Favorable forces include clinician dissatisfaction with 89% false positives driving costs/unnecessary interventions, plus medtech convergence of AI, photonics, and wearables.[4] It influences ecosystems by accelerating non-invasive fetal tech standards, potentially reducing cesareans/stillbirths, and fostering partnerships like GE to scale in hospitals worldwide.[2]
Raydiant is poised for FDA clearance and commercialization of Lumerah™, leveraging 2025 GE partnership and funding to launch pilots and expand globally, especially in high-burden regions.[2] Trends like AI-enhanced biophotonics, equitable medtech, and value-based care (cutting C-sections) will propel growth, with potential acquisition by giants like GE HealthCare. Its influence may evolve from innovator to category leader, transforming childbirth safety and echoing its founding mission to equip clinicians with reliable oxygenation data for fewer emergencies.
Raydiant Oximetry has raised $13.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $8.0M Series A | Avestria Ventures, Global Health Impact Fund | |
| Oct 1, 2021 | $5.0M Series A | Avestria Ventures |